VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An…

Overview of attention for article published in Frontiers in oncology, January 2020

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 57 Mendeley

So far, Altmetric has seen 1 X post from an account with 6,535 followers.

New research: VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized… https://t.co/2UnGq9

03 Mar 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.